In his weekly clinical update Dr. Griffin discusses how immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection, prevalence of SARS-CoV-2 and influenza coinfection and clinical characteristics among children and adolescents aged <18 years who were hospitalized or died with Influenza, WHO estimates of excess mortality associated with the COVID-19 pandemic, reconsideration of anti-nucleocapsid IgG antibody as a marker of SARS-CoV-2 infection post-vaccination for mild COVID-19 patients, impact of SARS-CoV-2 variants on inpatient clinical outcome, clinical features and burden of post-acute sequelae of SARS-CoV-2 infection in children and adolescents, similar SARS-CoV-2 Ct value distributions in anterior nares versus nasopharyngeal samples from symptomatic children during Delta and Omicron surges, early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19, effect of Nirmatrelvir/Ritonavir vs Placebo on COVID-19─related hospitalizations and other medical visits, COVID-19 Convalescent Plasma outpatient therapy to prevent outpatient hospitalization, bacterial co-infection and empirical antibiotic therapy in patients with COVID-19, association of time to surgery after COVID-19 infection with risk of postoperative cardiovascular morbidity, demonstration of stable clusters of symptoms in long COVID, and how longitudinal analysis of t cells in COVID-19 survivors with post-acute sequelae of COVID-19 reveals associations between individual symptoms and inflammatory indexes.
Click arrow to play
Download TWiV 967 (30 MB .mp3, 51 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Immunological dysfunction persists for 8 months following SARS-CoV-2 infection (Nature) 2:10
- Prevalence of SARS-CoV-2 and Influenza coinfection and clinical characteristics (CDC) 4:54
- WHO estimates of excess mortality associated with the COVID-19 pandemic (Nature) 9:31
- Reconsideration of anti-nucleocapsid IgG antibody as a marker of SARS-CoV-2 infection (OFID) 10:51
- Impact of SARS-CoV-2 variants on inpatient clinical outcome (CID) 14:16
- Clinical features and burden of post-acute sequelae of SARS-CoV-2 infection (OFID) 16:51
- Similar SARS-CoV-2 Ct value distributions in samples from symptomatic children (JPIDS) 19:06
- Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19 (CDC) 22:13
- Effect of Nirmatrelvir/Ritonavir vs placebo on COVID-19─Related hospitalizations (OFID) 32:45
- COVID-19 Convalescent Plasma outpatient therapy to prevent outpatient hospitalization (MedRxiv) 34:51
- Bacterial co-infection and empirical antibiotic therapy in patients with COVID-19 (OFID) 37:43
- Association of time to surgery after COVID-19 infection (JAMA) 39:28
- Demonstration of stable clusters of symptoms in long COVID (OFID) 40:19
- Paxlovid patient eligbiliity screening checklist (FDA)
- Longitudinal analysis of T cells in COVID-19 survivors with post-acute sequelae (OFID) 40:59
- Contribute to our MicrobeTV fundraiser at PWB 42:55
- Dr. Griffin’s treatment guide (pdf)
- Letters read on TWiV 967 43:36
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
Leave a Reply